Centre green-lights higher prices for cancer chemotherapy drugs as shortage continues: Report

Centre Green-Lights Higher Prices for Cancer Chemotherapy Drugs: Report

Centre green lights higher prices for cancer – India’s central government has approved price increases for certain cancer chemotherapy drugs, citing ongoing shortages of essential medications like cisplatin and carboplatin. This decision, reported by News18, follows a June 7 directive from the Department of Pharmaceuticals (DoP) to the National Pharmaceuticals Pricing Authority (NPPA) to invoke para 19 of the Drug Price Control Order (DPCO), 2013. The focus keyword, “Centre green lights higher prices,” is central to this policy shift, as it aims to address supply chain disruptions while balancing affordability for patients.

Reasons Behind the Price Hike Decision

The government’s approval stems from a critical need to secure the availability of platinum-based chemotherapy drugs, which are vital for treating cancers of the lung, ovarian, cervical, head and neck, bladder, and gastrointestinal systems. These drugs have faced persistent shortages, with pharmaceutical manufacturers struggling to meet demand due to rising costs of active pharmaceutical ingredients (APIs) and production challenges. The NPPA, tasked with regulating drug prices, has been reviewing 82 formulations to determine which require immediate price revisions.

“The Inter-Ministerial Committee (IMC) examined applications for 82 formulations and recommended price revisions for four, including carboplatin injection, cisplatin injection, and two anti-tetanus immunoglobulin injections, due to significant API cost increases and concerns over sustained availability,”

stated the DoP in its letter. The move highlights the interplay between supply chain stability and affordability, with the government prioritizing access to life-saving treatments over price caps.

Impact on Patients and Healthcare Providers

Cancer patients across the country now face a potential financial strain as prices for critical chemotherapy drugs rise. This comes at a time when many are already grappling with the high costs of treatment, especially in rural and semi-urban areas where healthcare infrastructure is limited. The decision has sparked concern among patient advocacy groups, who argue that the price hikes could exacerbate the burden on low-income families.

Medical professionals have also raised alarms, emphasizing that the shortage of these drugs has disrupted treatment schedules and led to delays in care. For instance, Kumar Ajit, a cancer patient, spent over a week searching for essential treatments in pharmacies across India, illustrating the real-world challenges faced by those in need. The NPPA has directed the DoP to consider the economic pressures on manufacturers, including exchange rate fluctuations and increased production costs, when setting new price guidelines.

Para 19 Mechanism and Future Implications

Para 19 of the DPCO allows the government to relax price controls when ensuring medicine availability or affordability becomes a top priority. This provision, previously used for drugs like insulin and paracetamol, has now been applied to chemotherapy medications. The DoP has suggested a 10% annual price increase with a 50% cap as a guideline, though cost increases will be the primary factor in determining final prices.

The policy shift raises questions about the long-term implications for drug pricing in India. While the government argues that price hikes are necessary to maintain supply chains, critics warn that it could lead to a cycle of continuous cost adjustments. The NPPA will now evaluate the maximum allowable price increases, with the aim of ensuring both accessibility and economic sustainability for pharmaceutical companies. This process will also set a precedent for future interventions in case of shortages.

Industry Response and Supply Chain Challenges

Pharmaceutical companies have expressed mixed reactions to the price revision. Some welcome the flexibility to adjust prices in response to rising input costs, while others fear it may reduce competition and lead to higher prices for patients. The shortage of platinum-based drugs has been attributed to a combination of factors, including export restrictions, production bottlenecks, and a lack of domestic manufacturing capacity.

Experts note that the decision reflects a growing reliance on para 19 to tackle supply crises, which has been a recurring issue in the Indian pharmaceutical sector. The DoP has emphasized the need for a uniform approach in evaluating price requests, ensuring that similar cases are handled consistently. This focus on standardization is expected to streamline the approval process and reduce administrative delays, though the long-term affordability of these drugs remains a key concern.

The ongoing shortage underscores the vulnerability of India’s healthcare system to global market fluctuations. With the government now allowing price increases for these essential drugs, the next step will be to monitor their impact on patients and adjust policies accordingly. This decision marks a pivotal moment in the balance between affordability, availability, and the financial sustainability of the pharmaceutical industry.